Osaze Udeagbala drives clinical science efforts for a phase 2 asset within Takeda Pharmaceuticals’ Gastrointestinal and Inflammation therapeutic area. Previously Osaze led early R&D business development efforts for Takeda’s GI Inflammation pillar. Osaze completed his medical training at New York University, and holds an MBA from MIT Sloan School of Management, as well as a Bachelor’s in Engineering summa cum laude from Cooper Union.